Uncovering Potential: BrainsWay's Earnings Preview
BrainsWay (NASDAQ:BWAY) is gearing up to announce its quarterly earnings on Wednesday, 2026-03-11. Here's a quick overview of what investors should know before the release.
Analysts are estimating that BrainsWay will report an earnings per share (EPS) of $0.04.
The announcement from BrainsWay is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Past Earnings Performance
During the last quarter, the company reported an EPS missed by $0.02, leading to a 3.95% increase in the share price on the subsequent day.
Here's a look at BrainsWay's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.04 | 0.05 | 0.01 | 0.01 |
| EPS Actual | 0.02 | 0.03 | 0.01 | 0.02 |
| Price Change % | 3.95 | 1.02 | 4.69 | 7.07 |
Stock Performance
Shares of BrainsWay were trading at $12.66 as of March 09. Over the last 52-week period, shares are up 394.37%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Delving into BrainsWay's Background
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
BrainsWay: A Financial Overview
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining BrainsWay's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.66% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: BrainsWay's net margin excels beyond industry benchmarks, reaching 11.59%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.27%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): BrainsWay's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.39% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: BrainsWay's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1.
To track all earnings releases for BrainsWay visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.